JAK1 and skin disorder: Treatment with a selective JAK1 inhibitor upadacitinib at a dose of 15 mg/day improved the patient’s pruritis and dermatitis (although to a lesser extent than the benefits her sons experienced with ruxolitinib); however, it was associated with side effects of rosacea and weight gain.